Early access program launched for the next generation of the ARESupa Universal Pathogenome Assay based on targeted next-generation sequencing (NGS) of native specimens First commercial orders ...

Genomics offers a foundation for understanding disease, but proteomics reveals invaluable insights by offering a real-time look at protein activity. Proteogenomic studies are advancing thanks to ...

A 46-year-old man was diagnosed with pleural effusion - a case of fluid accumulation around the lungs. According to his diagnostic tests, he was a confirmed case of stage 4 adenocarcinoma of the lung ...

SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer ...

Advanced lung cancer inflammation index (ALI) as a prognostic marker for locally advanced and metastatic cancer: A prospective study. Phase II study of disitamab vedotin (RC48) in combination with ...

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, ...

Even the most straightforward next-generation sequencing (NGS) experiments can be expensive and time-consuming. Thus, it’s a good idea to test your workflow on a few samples to make sure you’ll get ...

DUBLIN--(BUSINESS WIRE)--The "Genetic Screening Testing for Preventive Health Market - A Global and Regional Analysis: Focus on Test Type, Technology, Application, End User and Country-Level Analysis ...

EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic ...

The United States genetic testing market presents lucrative growth opportunities driven by increasing disease prevalence, technological advancements, and supportive regulatory frameworks.